Clinical trial
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
NCT02562443 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
- Lead sponsor
- Traws Pharma, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 2, 2015
- Completion date
- July 26, 2021
- Enrollment
- 372 (actual)
- Sites
- 158
Conditions
As the registry lists them; a condition with its own page is linked.
mds, myelodysplastic syndrome, raeb, refractory anemia with excess blasts